Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027

Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data ...
RenewEconomy

Webinar: Are we overbuilding the grid?

Watch the webinar to explore whether Australia’s grid is being overbuilt or underfunded, and how EVs, batteries and new ...
The Manila Times

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Gain Therapeutics, Inc. (Nasdaq: GANX) ('Gain”, or the 'Company”), a clinical-stage biotechnology company leading the ...

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

‘Your hands would be burning’: How a gravely ill veteran took on the Commonwealth and won

Bob Caesar was poisoned by chemicals he had to use in the Royal Australian Air Force. The government fought every step of the ...
RenewEconomy

Energy Insiders Podcast: The man who saved solar and helped kill coal

Smart Energy Council's John Grimes on the death of coal power in Australia, panel by panel, home battery by home battery. He ...